ロード中...
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
The combination of targeted therapy with BRAF and MEK inhibitors has become the standard of care in patients with BRAF(V600E) mutant melanoma, but responses are not durable. In addition, the impressive clinical benefits with anti-PD-1 and anti-PD-L1 antibodies (Ab) in patients with heavily pretreate...
保存先:
| 出版年: | Oncoimmunology |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5006894/ https://ncbi.nlm.nih.gov/pubmed/27622011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1052212 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|